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Antibiotics and vaccines are the two most successful medical countermeasures
that humans have created against a number of pathogens. However a select few
e.g., Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB) have
evaded eradication by vaccines and therapeutic approaches. TB is a global public health
problem that kills 1.4 million people per year. The past decade has seen significant
progress in developing new vaccine candidates, but the most fundamental questions in
understanding disease progression and protective host responses that are responsible
for controlling Mtb infection still remain poorly resolved. Current TB treatment requires
intense chemotherapy with several antimicrobials, while the only approved vaccine is the
classical viable whole-cell based Bacille-Calmette-Guerin (BCG) that protects children from
severe forms of TB, but fails to protect adults. Taken together, there is a growing need
to conduct basic and applied research to develop novel vaccine strategies against TB.
This review is focused on the discussion surrounding current strategies and innovations
being explored to discover new protective antigens, adjuvants, and delivery systems in
the hopes of creating an efficacious TB vaccine.
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system
TUBERCULOSIS DISEASE AND EPIDEMIOLOGY
Tuberculosis (TB) has been one of the major causes of morbid-
ity and mortality worldwide for centuries. TB takes a devastating
toll on human lives with 2.2 billion people, representing one-third
of the world’s population, currently infected with the causative
agent, Mycobacterium tuberculosis (Mtb), and an alarming 1.4
million deaths each year (WHO, 2012). TB is a complicated
disease with multiple infectious sites and a wide range of clin-
ical disease manifestations. Approximately 70% of Mtb-exposed
individuals will clear the bacteria, while the remaining 30% will
get infected. In about 90% of those infected, Mtb either gets
controlled by the immune response or remains viable but phys-
iologically inactive or dormant in the host. People infected with
dormant Mtb are diagnosed as having latent TB or non-clinical
TB infection (LTBI). It is thought that 5–10% of LTBI cases pro-
gresses to active disease. Reactivation of latent TB may occur
during the chronic stage of infection, possibly due to the change of
the host’s immune response or because of exogenous reinfection
withMtb.
Immunodeficiency in individuals co-infected with the human
immunodeficiency virus type 1 (HIV-1) causes a breach in host
containment of Mtb resulting in increased incidence of reac-
tivation of TB. With the spread of human immunodeficiency
virus (HIV) and dramatic increase in the number of cases
of multidrug-resistant (MDR-TB) and extremely drug-resistant
(XDR-TB) infections, the WHO in the early 1990’s declared TB
as a re-emerging infectious disease. WHO estimates that there
are more than 8.7 million new cases of active TB each year
(WHO, 2012) and about 2.6 million new cases of HIV infection
with 1.8 million AIDS-related deaths per year (UNAIDS, 2010).
Alarmingly, about 14million individuals worldwide are estimated
to be dually infected with TB-HIV (Getahun et al., 2010). TB
is the largest cause of death in AIDS patients, (∼29%), most of
which (99%) occur in developing countries (Pawlowski et al.,
2012). In HIV/TB co-infection, both pathogens combat the host’s
immune responses through various mechanisms. HIV depletes
CD4+ T cells of the lamina propria of the gastrointestinal tract
(Clayton et al., 1992; Brenchley and Douek, 2008) resulting in
T cell dysfunction in cytokine production and cytotoxic activity,
and therefore compromising the immune response. HIV/TB co-
infection dramatically increases the risk of latent TB reactivation
by 20- to 37-fold, and is therefore the most powerful risk factor
for latent TB reactivation (Getahun et al., 2010).
Antimicrobial therapy with various regimens is used to treat
TB. However, their inadequate and inappropriate use has trig-
gered an increase in MDR-, XDR-TB, and total drug-resistant
(TDR-TB) cases worldwide, adding to the challenges of TB erad-
ication and healthcare cost (Caminero, 2010). Based on drug
resistance data from 114 countries and two-regions of China, it
was estimated that ∼500,000 MDR-TB cases emerged in 2006,
representing 4.8% of all cases of TB (WHO, 2007). While drug-
sensitive strains ofMtb in immunocompetent patients are treated
for at least 6 months with multiple antibiotic regimens to achieve
efficient clearing of the mycobacteria by the host, in MDR-TB or
XDR-TB cases second-line drugs are used, with a higher risk of
adverse effects and lower potency, raising the costs of treatment
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for patients carrying MDR strain dramatically (Dye et al., 2002;
Mukherjee et al., 2004). In addition, although multidrug com-
binations treat TB successfully, the used multidrug regimens are
ineffective against MDR-, XDR-, and TDR-TB and have not pre-
vented transmission of disease in endemic regions due to high
infectivity rate and lack of rapid diagnostic tests to detect active
TB infection.
The ability of the mycobacterium to enter latency with no clin-
ical symptoms of disease leads to poor, untimely diagnosis and
treatment, which negatively impacts TB elimination strategies in
the United States and many other countries (ATS/CDC/IDSA,
2000, 2005). The tuberculin test (TST), which is a conven-
tional method for detection of Mtb infection, is known to have
important limitations. TST was shown to cross-react with Bacille-
Calmette-Guerin (BCG) vaccine and with non-TB mycobacterial
(NTM) species and is particularly difficult to interpret in BCG-
vaccinated foreign-born individuals from TB-endemic countries
(Agger and Andersen, 2002; Shah et al., 2012). Also, inter-reader
variability in result interpretation affects the outcome of TST
specificity, affecting the treatment schedule and therefore the
overall control of disease.
Clearly, better preventive measures that block Mtb transmis-
sion are needed, including vaccines that prevent infection (pro-
phylactic, infection-preventing) or prevent further development
of disease into active state (therapeutic, disease-blocking).
IMMUNE RESPONSE TO TB AND ITS IMPLICATION FOR
VACCINE DEVELOPMENT
The often-encountered difficulties surrounding the development
of vaccines against TB are primarily associated with the limited
knowledge of the protective immunity that is needed to clear the
infection as well as the lack of identification of antigens that when
targeted by the immune response will result in protection against
disease development.
After inhalation of Mtb through aerosol particles, the
mycobacteria are phagocytosed by alveolar macrophages and den-
dritic cells (DC) and subsequently transported to the site of infec-
tion, mainly the lungs. Inside the macrophage, Mtb is trapped
in the phagosome where it replicates until the innate immune
response activates the macrophage in an effort to control the
pathogen. During this time, the bacteria are capable of arresting
phagolysosome formation, through a few known mechanisms,
preventing bacterial death from high pH and hydrolytic enzymes
present in phagolysosomal compartment. In DC, the pathogen
is carried to the draining lymph nodes, where Mtb–derived anti-
gens are presented to T lymphocytes and Mtb antigen-specific
T cells that are generated. These cells recirculate and induce for-
mation of granulomas in the lung. The granuloma is comprised
of a large number of immune cells that altogether with a fibrous
cuff restrain bacterial cells from spreading. Although the innate
immune response slows down the physiological dynamics ofMtb,
it rarely leads to complete killing of the bacteria, and most often
it promotes latency, whereby the bacteria is contained in the
granuloma.
TB vaccine candidates should elicit cellular immune responses
that are important in controlling Mtb. T lymphocytes are gen-
erally believed to mediate immunity against TB based both
on animal models of infection and human data. Interferon-γ
(IFN-γ) producing CD4+ T helper cells (Th1) and antigen-
specific CD8+ T cells clearly play an important role in immunity
against TB (Cooper et al., 1993; Flynn et al., 1993; Munk and
Emoto, 1995; Bastian et al., 2008). The MHC class I restricted
T cells also participate in resistance to Mtb infection (Flynn
et al., 1992). This resistance appears to be mediated by grazymes
A and B and by granulysin (Canaday et al., 2001). Tumor necro-
sis factor-α (TNF-α) and p55 receptor expression are associ-
ated with TB resistance (Flynn et al., 1995). CD4+ Th2 cells
do not generally participate in mediating protection against
TB, but a role for B cells in host defense is becoming appar-
ent (Maglione and Chan, 2009) as B cell deficient mice were
found to be more susceptible to TB (Vordermeier et al., 1996;
Maglione et al., 2007).
IL-17-producing T helper cells (Th17 cells) have been impli-
cated in the early phase adaptive immunity and host defense
against Mtb (Khader et al., 2007). In addition, Th17 cells were
also implicated in human and murine responses to BCG vaccina-
tion (Scriba et al., 2008; Cruz et al., 2010). Mtb challenge of mice
vaccinated with BCG resulted in an increase in interleukin IL-17,
TNF-alpha, IL-6, and MIP-2 expression along with lung tissue
damage (Cruz et al., 2010). Based on the possible role of Th17 in
Mtb infection, it is proposed that a protective TB vaccine will need
to induce both Th1 and Th17 memory responses. It is hypothe-
sized that the vaccine-elicited Th17 cells will be sequestered in the
lung and upon subsequent challenge with Mtb, the Th17 mem-
ory cells will proliferate rapidly, producing IL-17 and triggering
the local expression of chemokines that will recruit protective
Th1 cells for the clearance of Mtb in the lungs. Therefore, a
Th17 response will clearly be beneficial since it will accelerate the
recruitment of Th1 cells for rapid bacterial clearance. Current
vaccine studies are now focusing on IL-17-producing memory
cells in the hopes of improving vaccine strategies against TB in
humans.
INNATE IMMUNITY
There is a highly probable link between innate and adaptive
immune response toMtb and a better understanding of this inter-
action is critical in the development of an effective vaccine. The
γ/δ T cells respond rapidly to microbial epithelial invasion and
are considered a component of innate immunity (Haregewoin
et al., 1989; Constant et al., 1994). γ/δ T cells produce cytokines
such as IFN-γ, which is important for inducing type 1 immunity.
BCG immunization induces human memory γ/δ T cells charac-
terized by a more rapid and potent secondary responses, which
suggest that these cells have a direct adaptive immune role in
mycobacteria infections in humans (Spencer et al., 2008).
Another component of innate immunity to mycobacterial
infections aremucosal associate invariant T cells (MAIT) (Porcelli
et al., 1993). Both TB-exposed and unexposed individuals have
Mtb-reactiveMAIT cells (Gold and Lewinsohn, 2011). MAIT cells
are thought to be innate T cells based on their restricted expres-
sion of the semi-invariant Va7.2 T cell receptor (TCR) and
their activation via the non-polymorphic HLA-Ib molecule MR1.
Because MAIT are capable of producing IFN-γ directly ex vivo
in response to Mtb-infected cells, MAIT may play a role in the
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control of the bacterium. Questions remain, however, whether
MAIT cells represent an Mtb-reactive innate T cell population
that can supply an early source of IFN-γ in the innate control of
TB disease as well as providing aid in the acquisition of an optimal
adaptive Th1 immune response.
Apoptosis and autophagy are innate immune defense mech-
anism against mycobacteria by possibly suppressing bacterial
replication and promoting DC presentation of bacterial antigens
to T cells for better T cell induction and protection in vivo. The
Mtb pathogen, however, has evolved to evade death by apopto-
sis of macrophages and neutrophils and this evasive maneuver
by Mtb is thought to contribute to its virulence (Keane et al.,
2000; Blomgran et al., 2012). Infection of macrophages with
“pro-apoptotic” Mtb mutants (e.g., nuoG and secA2) leads to
enhanced apoptosis and mice infected with the mutants showed
augmented induction of CD4+ and CD8+ T cells (Hinchey et al.,
2007; Blomgran et al., 2012).
Autophagy is an essential host defense mechanism against
microbes and plays an important role in host innate and adaptive
immunity. Activation of autophagic pathways in macrophages
causes mycobacterial phagosomes to become mature phagolyso-
somes, which can compromise the survival of intracellular
mycobacteria. However,Mtb has evolved mechanisms to suppress
autophagic pathways in macrophages (Deretic et al., 2009).
Since the correlates of protective immunity against TB are not
known, it is imperative to conduct human studies that will enable
us to identify host and bacterial determinants that play critical
roles in protection against TB infection and disease. A current
prospective study led by Willem Hanekom and colleagues have
established a cohort of 6363 South African adolescents. 53% were
infected with Mtb at baseline and during 2 years of follow-up, 76
of these participants developed TB disease. Blood samples were
collected and will be used to compare host responses between
individuals who developed disease and those who have remained
healthy. The availability of this cohort will allow us to address host
responses that are involved in TB. Initial studies of this cohort
showed that high bacterial load was associated with impairment
of antigen-specific T cell responses in Mtb-infected individuals
(Day et al., 2011). Knowledge of host determinants of protec-
tion against TB disease could impact TB control not only in the
design of new vaccines but also prophylactic therapy for infected
persons.
EXISTING TB VACCINE—BCG
Despite immense efforts in TB vaccine research we continue to
immunize with Mycobacterium bovis bacillus Calmette-Guerin
(BCG) vaccine (Calmette, 1931), which was approved for human
use at the beginning of the 20th century. BCG was proposed
as a live vaccine against TB by Albert Calmette and Camille
Guérin only few years after the discovery of the intracellular
pathogen Mtb as the causative agent of TB by Robert Koch in
1890 (Calmette et al., 1907). M. bovis BCG was generated after
continual passaging of the parentalM. bovis strain for 13 years (a
total of 230 passages) in media containing bile, which resulted in
an attenuated strain with reduced virulence in animals (Calmette
and Guerin, 1920). BCG vaccine production started in 1927 that
then led to generations of daughter BCG strains with different
genomic composition (Behr, 2002). BCG vaccine is administered
worldwide as a single intradermal inoculation dose.
The use of heat-inactivated or live attenuated pathogens was
the preferred choice for many years in traditional vaccinology
since they contain a vast array of antigens. Because of this, a broad
and diverse immune response is induced resulting in protection
against the pathogen. However, BCG vaccination affords only
partial protection in humans. BCG protects against miliary TB
and meningitis TB in infants (Rodrigues et al., 1993; Trunz et al.,
2006), but fails to protect against pulmonary and latent TB in
adults of both sexes and all ages, including children (ICMR, 1999;
Narayanan, 2006). The variable efficacy of BCG, ranging from 0 to
80% in randomized control trials is attributed to a number of fac-
tors, including geographical location of human population, loss
of virulence genes essential in protective immunity, an insufficient
induction of CD8+ T cell response, exposure to environmental
(non-tuberculous) mycobacteria or helminthic infection prior to
BCG vaccination (Fine, 1988; Agger and Andersen, 2002; Lalor
et al., 2009; Rowland and McShane, 2011).
TB VACCINES IN CLINICAL TRIALS
Due to protection conferred by BCG in childhood, current vac-
cines strategies in clinical trials are either focused on engineering
BCG to be more immunogenic or boosting prior BCG vacci-
nation with new vaccine regimens in the hopes of increasing
protection (Table 1). There are also a few new live vaccines being
tested to entirely replace BCG due to the associated risk of infec-
tion with the viable vaccine in TB-HIV population (von Reyn
et al., 2012).
LIVE MYCOBACTERIUM-BASEDVACCINES AIMING TO REPLACE BCG
New-generation mycobacterial vaccine vectors utilize current
BCG as backbone to express known T-cell immunogens from
virulent Mtb or mutants of BCG that are capable of escap-
ing the phagosome to induce CD8+ T cell response are being
tested as vaccine candidates. BCG shares many proteins in com-
mon with Mtb, however many of these proteins are not well
recognized by vaccinated humans or animals. One such anti-
gen is the molecule known as antigen 85 B (Ag85B), a major
secretory protein produced by Mtb previously shown to induce
protection to TB in mice and guinea pigs (Horwitz et al.,
1995). Although BCG produces this protein, little or unde-
tectable immune response to this molecule is observed after
vaccination. However, a recombinant BCG vaccine (rBCG30)
overexpressing and secreting ∼5.5 fold more Ag85B than con-
ventional BCG induced an order of magnitude greater immune
response when compared to the parental BCG vaccine. A Phase
I clinical trial with rBCG30 has been successfully completed
(Horwitz et al., 2000; Hoft et al., 2008). Another interesting
recombinant BCG-based vaccine is VMP1002 (Kaufmann, 2012;
Kaufmann and Gengenbacher, 2012; Ottenhoff and Kaufmann,
2012). VMP1002 was engineered using specific properties of
listeriolysin O, a secreted thiol-activated cholesterol-binding
hemolysin from Listeria monocytogenes (Table 1) (Geoffroy et al.,
1987). This protein forms multimeric forms that allow engi-
neered VMP1002 cells to escape from phagolysosomes (pH5.5)
to the cytosol of the host, where the microbial vaccine antigens
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can be processed by the MHC Class I machinery and then
presented to CD8+ T cells (Geoffroy et al., 1987; Hess and
Kaufmann, 1999; Horwitz and Harth, 2003; Cai et al., 2004;
Olsen et al., 2004).
BOOSTER VACCINES TO AUGMENT BCG IMMUNITY
The rationale behind this strategy is to boost anti-TB immu-
nity induced by prior vaccination with BCG. The goal is to
continue implementing BCG immunization in neonates but sub-
sequently boost at an older age with another TB vaccine regimen
to augment immunity and protection afforded by prior BCG
vaccination. Several booster vaccines could be used including
recombinant viral poxviruses and adenoviruses vectors, which
are highly immunogenic and currently being evaluated as vac-
cine delivery systems for HIV/AIDS and other diseases (Cosma
et al., 2007). MVA85A is a replication-deficient vaccinia virus
Ankara (MVA) used as delivery system for the mycobacterial anti-
gen 85A, which augmented BCG-induced immunity in humans
(McShane et al., 2004).
A replication-deficient strain of adenovirus used a delivery
vector elicits high magnitude and functional CD4+ and CD8+
T cell responses to a vaccine candidate (McShane et al., 2002).
Indeed the engineered Ad5Ag85A, a recombinant adenovirus
serotype 5 (Ad5) vaccine vector expressing the Mtb antigen 85A
is currently being tested in a phase I safety and immunogenic-
ity study in BCG-vaccinated and-nonvaccinated healthy adults in
Canada (Wang et al., 2004b). Another variation of this vaccine
uses a non-replicating adenovirus serotype 35 expressing anti-
gens 85A, 85B, and TB10.4 and is in clinical trial under the name
of AERAS-402 (Abel et al., 2010). The advantage of Ad35 over
other delivery viral vectors is the low frequency of anti-adenovirus
neutralizing antibodies and low-levels of pre-existing immunity
found in humans.
Another strategy to boost BCG-induced immunity is to use
protein-based subunit vaccines as boosting agents. Subunit vac-
cines currently in clinical trials include Mtb72F/ASO1/ASO2A,
which consists of a 72 kDa recombinant protein containing
Mtb32 (Rv1196) andMtb39 (Rv0125) antigens previously shown
to induce strong CD4+ and CD8+ T cells responses in labo-
ratory animals but more importantly, in healthy, PPD-positive
individuals (Skeiky et al., 1999, 2000, 2005). The recombinant
polyprotein is used with the AS02A adjuvant, an oil-in-water
emulsion with 3-deacylated monophosphoryl lipid A (MPL) and
QS-21 detergent (Pichichero, 2008). Another vaccine candidate
in clinical trial is AERAS-44, which is a fusion protein called
Hybrid 1 consisting of antigens 85B (Olsen et al., 2004) and
TB10.4 (Rv0288) (Dietrich et al., 2005). The H1 vaccine com-
bined with adjuvants IC31, a synergistic combination of single-
stranded oligodeoxynucleotide and a peptide (KLKL5KLK) that
induces the Toll-like receptor-9 (TLR9) (Schellack et al., 2006)
had promising preclinical data in that the vaccine elicited Th1
responses and increased protection against Mtb in mice (van
Dissel et al., 2010; Aagaard et al., 2011). H56-IC3 is another
candidate vaccine in early human trials. This promising vac-
cine formulation contains novel latency-associated TB antigen,
Rv2660c, along with Ag85B, ESAT-6, and the IC31 adjuvant
(Aagaard et al., 2011).
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THERAPEUTIC VACCINES
Therapeutic vaccines are being developed to treat people already
infected with Mtb as adjunct therapy. However, immunother-
apy with Mtb bacterial components poses a health risk since
TB patients when inoculated with high doses of Mtb anti-
gens can have adverse reactions similar to a tuberculin shock,
which was first described by Robert Koch over 100 years ago
(Rook and Stanford, 1996). More recently one of us has shown
that a single recombinant molecule of Mtb can trigger tox-
emic reaction in guinea pigs previously infected with Mtb
(Reece et al., 2005). Therefore, careful selection of the candi-
date antigen to be used in immunotherapeutic protocols is highly
recommended.
Nonetheless, immunotherapeutic vaccines are being tested in
clinical trials. A candidate therapeutic vaccine that is under evalu-
ation is RUTI, a heat-inactivated Mtb cellular fragment, designed
to shorten the chemotherapy of LTBI (Cardona, 2006; Vilaplana
et al., 2010, 2011). This phase II study compares three different
doses of RUTI given after 1 month of isoniazid in HIV-positive
and HIV-negative adults showed that the vaccine was well toler-
ated, with the most common adverse events being mild injection-
site reactions. Efficacy of RUTI vaccine regimen is currently being
evaluated.
Another therapeutic vaccine candidate is ID93/GLA-SE
(Bertholet et al., 2008, 2010). This product is a fusion of four
mycobacterial antigens, including one latency antigen into a syn-
thetic TLR-4-agonist, glucopyranosyl lipid A (GLA) adjuvant that
combines an innate signal with a potent Th1-inducer (Table 1)
(Coler et al., 2011; Pantel et al., 2012). Testing in hyper-susceptible
inbred mouse strain (SWR/J) and cynomolgus monkey mod-
els showed that ID93/GLA-SE vaccination augmented the ther-
apeutic effect of rifampin and isoniazid (Coler et al., 2012).
Therapeutic vaccination with ID93/GLA-SE reduced lung bacil-
lary loads and pathology and shortened the treatment duration
by one-third when compared to the treatments with antimicro-
bials alone, although the magnitude of therapeutic vaccination in
monkeys appeared to be modest.
Finally two heat-inactivated mycobacterial strains M. indicus
pranii (MIP) (Singh et al., 1991; Patel et al., 2002) and M. vac-
cae (Waddell et al., 2000; Vuola et al., 2003; Xu et al., 2009; Yang
et al., 2011) have been tested in combination with the chemother-
apy for Mtb infection. Administration of various doses of MIP
subsequent to TB chemotherapy seems to decrease the inflam-
matory responses and lead to amelioration of lung pathology in
tested animal models (Gupta et al., 2012).M. vaccae administered
in a multiple-dose series format promoted significant protection
against TB in HIV-infected adults who have been vaccinated with
BCG during childhood (von Reyn et al., 2010, 2012). Therefore
this protocol represents a potential immunotherapeutic strategy
against TB for a large population of patients that are co-infected
with TB and HIV.
NOVEL TB VACCINE APPROACHES
Despite the testing of several new TB vaccine candidates in human
trials, there is no guarantee that any of these vaccines will be bet-
ter than BCG. There are still gaps in our knowledge of the human
correlates of protective immunity and our understanding of
host-pathogen relationships especially immune evasion strategies
employed byMtb. The more insights we gain in these areas of TB
research the better we are equipped at creating an effective vaccine
against TB.
In the next sections we will emphasize novel approaches
and strategies in TB vaccine development, highlighting scien-
tific issues that need to be addressed in this complicated field of
vaccine development (Figure 1).
NEW ANTIGEN DISCOVERY STRATEGIES
Traditional methods for identification of Mtb vaccine candi-
date molecules including those that identified candidate antigens
that found in culture filtrate (CF) were later confirmed to elicit
immune responses in animal hosts infected with TB. Figure 2
summarizes current and novel antigen discovery strategies of
candidate vaccine for TB.
New technologies and developments in bioinformatics have
made possible the search for novel vaccine candidate antigens
in silico, based on genomic sequence of the pathogen (Rappuoli,
2000; Rappuoli et al., 2011). This “reverse vaccinology” is an
unbiased approach that uses known homologous sequence data
to search for multiple immunogenic antigens. Seventy new Mtb
class I CD8+ T cell epitopes were identified and the immuno-
genicity of 18 of them have been assessed with tetramers. There
was broad IFN-γ, IL-2, and TNF-α responses to these epitopes on
cured TB patients suggesting that there is a much broader CD8+
response than previously appreciated (Tang et al., 2011).
Based on findings that human T cells from TB patients were
shown to recognize hyperconserved epitopes that are thought
to benefit the Mtb pathogen (Ernst, 2012), one can hypothesize
that human T cell recognition of previously discovered hypercon-
served epitopes are non-protective and that those that are variable
are more closely associated with protective immunity. On this
premise, Joel Ernst and colleagues seek to identify immunogenic
variable T cell epitopes using in silico analyses that may be pro-
tective from sequences of 180 phylogenetically-diverse strains of
Mtb, and the most diverse regions of the Mtb genome will be
identified. T cell responses will be assayed to synthetic peptides
having sequences matching those in the subject’s infecting iso-
late, to identify which of the predicted epitopes are true targets of
FIGURE 1 | Approaches of vaccine development to TB discussed in the
present review.
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FIGURE 2 | Strategies of antigen discovery of TB vaccine candidates.
human T cell recognition. It is anticipated a large set of immuno-
genic variable epitopes will be discovered and potentially could be
used as vaccine immunogens to elicit protective T cell responses.
Identifying vaccine antigens from active TB
Antigens that are recognized by host immune cells during active
TB, when Mtb is replicating, are potential immunologic targets
for controlling the pathogen. Strategies to identify these impor-
tant antigens represent an alternative to current approaches to
vaccine antigen discovery. The focus of our laboratory for a num-
ber of years has been to search for antigens recognized by host
immune cells during active Mtb infection. We have accumulated
a portfolio of potential vaccine antigens present in various bodily
fluids of humans and animals infected with TB (Mukherjee et al.,
2005; Kashino et al., 2008a; Napolitano et al., 2008). Antigens
expressed and secreted in urine of patients with pulmonary TB
(Kashino et al., 2008b) and infected mice (Mukherjee et al., 2005)
were identified using 2D-gels followed by mass spectrometry.
Four unique peptide-homologs to Mtb proteins were identified
in the urine of pulmonary TB patients (Kashino et al., 2008b;
Napolitano et al., 2008) with one of the immunogens a molyb-
dopterin biosynthesis protein (MoeX, Rv1681; MT_1721) unique
to Mtb complex, and the other three antigens are present in all
mycobacterial members with ∼70% homology. These are cur-
rently being evaluated and preliminary preclinical studies showed
that the subunit and DNA vaccine expressing MT1721 was highly
immunogenic, capable of eliciting both CD4+ Th1 and CD8+
T cell responses (Cayabyab et al., 2012).
Protective antigens that will prevent latent TB
To develop an efficacious TB vaccine, vaccinologists must find a
solution to the problem of latency and immune evasion in vaccine
design. One logical approach is to identify antigens preferentially
expressed during latency. Several promising vaccine antigens have
been identified that could be targets of the host immunity during
chronic infection. A subunit vaccine (H56) containing the com-
bination of early secretory Ag85B/ESAT-6 and latent (Rv2660c)
antigens protected mice against latent and reactivation TB and
the H56 vaccine lowered bacterial burden in mice already infected
withMtb (Aagaard et al., 2011).
Identifying antigens that induce CD8+ T cells
Numerous studies suggest that CD8+ T cells will be needed to
protect against TB. Mtb efficiently induces Ag-specific CD8+
T cells to various MHC I-restricted epitopes (Billeskov et al.,
2007; Begum et al., 2009; Woodworth et al., 2011), and Mtb-
specific CD8+ T cells are important in protection to mice in
secondary Mtb infection (Wang et al., 2004a; Wu et al., 2008).
A novel strategy to identify CD8+ T cell antigens is a major
research effort of our and other laboratories. To discover poten-
tial CD8+ T cell vaccine antigens, we eluted Mtb-specific pep-
tides bound to major histocompatibility complex (MHC) class
I molecules from spleens of infected mice and identified several
candidate antigens. Preliminary immunogenicity studies revealed
that one of the identified T cell antigens, MT0401, was highly
immunogenic and recognized in Mtb-infected mice. Vaccination
of mice with the new recombinant VRC8400 DNA vaccine vector
and Ad5 vectors expressing the MT0401 antigen elicited potent
CD4+ and CD8+ T cell responses (our unpublished observa-
tions). The protective efficacy of the vaccine vectors expressing
MT0401 antigen in mice and guinea pigs are currently being
evaluated.
NOVEL ADJUVANTS TO STIMULATE VACCINE-INDUCED TB IMMUNITY
There are only a few adjuvants approved for human use and sub-
unit vaccines mixed with those adjuvants largely elicit CD4+
T cell responses and humoral immunity and stimulate poor
CD8+ T cell responses. Since there is general consensus that an
effective vaccine againstMtb will require both CD4+ and CD8+
T cells, and perhaps to some extent the humoral arm of the
immune response, it is critical that new adjuvants be tested that
will be more potent than formulations currently used clinically
(Figure 3).
Glucopyranosyl-lipid A (GLA) is a non-toxic, synthetic
molecule, homogeneous to monophosphoryl lipid A from
Salmonella minnesota (MPL) that has been recently developed
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FIGURE 3 | Delivery systems used in vaccine development for TB.
by the Infectious Disease Research Institute (IDRI), Seattle, WA.
GLA formulated with squalene forms a stable oil-in-water emul-
sion (GLA-SE). This formulation, similar to MPL-SE, is a Th1-
stimulatory adjuvant shown to be effective in preventing and
reducing disease caused by Leishmania parasites (Bertholet et al.,
2009). A GLA-SE formulation includes a polyprotein TB vaccine
candidate, which includes four Mtb antigens (Rv2608, Rv3619,
Rv3620, and Rv1813) was recently developed and tested by sci-
entists at IDRI. This formulation showed promising results in
protection experiments performed in mice challenged with vir-
ulent (Windish et al., 2011). IDRI has announced a new part-
nership with Aeras to develop this candidate and a phase I trial
is scheduled to start this year (http://www.idri.org/press-5-9-12.
html).
Carbomers (polymers of acrylic acid) have been used in the
pharmaceutical industry to achieve controlled release of medi-
cations in tablets and as a bioadhesive in mucosal applications.
Immunization with a soluble antigen containing a carbomer-
based adjuvant induced antigen-specific T cell producing both
Th1 and Th2 cytokines including high titers of IFN-γ, IL-2,
and IL-4, and drove a Th1 isotype-switched antibody response
(Krashias et al., 2010; Dey et al., 2012). The underlying mech-
anisms responsible for the adjuvant properties of carbomers
and the functionality and the protective capacity of the T cell
responses induced by subunit antigens mixed in carbomers need
to be investigated prior to the use of carbomers as a TB vaccine
adjuvant.
TLR-9 control multiple DC functions and adaptive immune
responses in addition to their role in innate immunity. TLR liga-
tion represents a novel approach to augmenting TB vaccines. The
CpG 7909, a TLR9 ligand, has been shown to be a potent adju-
vant to pneumococcal vaccines in early human immunogenicity
studies (Sogaard et al., 2010) and is now being tested in Phase I
trials as a vaccine adjuvant in the treatment of cancer (Adams,
2009). Subunit vaccines with CpG 7909 is expected to generate a
strong broad adaptive immune response, includingT helper 1 and
CD8+ T cells, important feature of a vaccine needed to protect
against TB.
Elicitation of protective mucosal immune responses to
mucosal pathogens such asMtb is hindered by endogenous regu-
latory systems that suppress immune responses to foreign anti-
gens on mucosal surfaces. To bypass those regulatory systems,
mucosal adjuvants are needed and a strong mucosal adjuvant, LT-
IIb (T13I), a non-toxic type II heat-labile enterotoxin currently
being tested (Lee et al., 2011; Casey et al., 2012) could potentially
be used as an adjuvant to enhance subunit TB vaccines.
Mycobacterium-induced apoptosis is an innate defense mech-
anism that can prevent the bacteria from establishing in the host,
perhaps because apoptosis can promote DC-mediated presenta-
tion of bacterial antigens to T cells and generation of adaptive
anti-bacterial immunity. How apoptosis is regulated and restricts
Mtb replication and whether it can be manipulated to enhance
vaccination is the focus of current investigations (Behar et al.,
2011a,b). Sam Behar and colleagues are exploring eicosanoids
as a pro-apoptotic agent since these compounds play a role in
immunity to mycobacteria by regulating activation of infected
macrophages leading to control of intracellular bacterial replica-
tion. An attractive vaccination strategy would be to pharmacolog-
ically manipulate the eicosanoid biosynthetic and cell signaling
pathways to enhance apoptosis of infected macrophages. By pro-
moting apoptotic death, it may be possible to increase the safety
and the efficacy of attenuated bacterial vaccines.
The glycosphingolipid α-galactosylceramide (α-GalCer, also
known as KRN7000) is a synthetic analog of the marine natural
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product agelasphin that activates both human and mouse invari-
ant natural killer T cells to produce immune-regulatory cytokines
(Sogaard et al., 2010). BCG with stably incorporated α-GalCer
was found to stimulate increased maturation of DCs and aug-
mented the priming of CD8+ T cell responses that corre-
lated with better protection against Mtb challenge in mice
(Venkataswamy et al., 2009). The clinical utility of α-GalCer as
a TB vaccine adjuvant needs to be determined.
Vaccine adjuvants are needed to activate DC for T cell prim-
ing, but these adjuvants simultaneously induce the expression
of suppressive genes including T regulatory cells and inhibitory
receptors (e.g., PDL1 and PDL2) and their signaling pathway
molecules (e.g., SOCS1, SOCS2, and IRAK-M). To maximize the
immunostimulatory potential of vaccines, it may be necessary to
downregulate inhibitory receptor signaling pathways activated by
adjuvants and vaccine vectors. The use of siRNA that will block
the immunosuppressive activity of inhibitory receptors as a com-
ponent of a vaccine formulation is currently being tested (Lee,
2012a). A new method for in vivo gene silencing being explored
makes use of Glucan encapsulated siRNA Particles (GeRP), which
is a packaging system of charged molecules, including protein
antigens and adjuvant compounds along with siRNA inside the
glucan shells (Aouadi et al., 2009). The resulting particles allow
co-delivery of a complete vaccine formula to a DC via the
receptor Dectin-1. The silencing capability of GeRP and its abil-
ity to augment vaccine-induced immune responses are being
assessed.
Lactoferrin, an iron binding glycoprotein, has been previ-
ously shown to promote maturation of T- and B-lymphocyte and
immature DC, and enhance the ability of macrophages and DCs
to stimulate antigen-specific T-cells. Lactoferrin is currently being
tested as an adjuvant because of its ability to enhance the gen-
eration of antigen-specific DTH responses (Actor et al., 2009).
Lactoferrin mixed with BCG vaccine promoted host protective
responses that surpasses activity of the BCG vaccine alone as
determined by decreasing pulmonary pathology upon challenge
with virulent Mtb (Hwang et al., 2011). Production of IL-17 and
IFN-γ is increased while IL-10 production is decreased in mice
vaccinated with BCG/lactoferrin compared to the group vacci-
nated with only BCG. This study illustrates adjuvant activity of
lactoferrin by enhancing BCG immunogenicity.
Novel mycobacterial vectors
The next generation of mycobacterial vectors should be more
immunogenic than BCG by eliciting better innate and adap-
tive immune responses that prevents primary TB as well as
LTBI through effective elimination of the Mtb bacilli. The use
of gain-of-function or loss-of-function screens has enabled the
identification of several classes of potentially more immunogenic
BCG mutants and mycobacterial vectors. One class of mutants
are those that inhibit apoptosis of macrophages and Th1 response
which has been linked to virulence and immune evasion by
Mtb. Using gain-of-function screens, several anti-apoptotic genes
have been identified including nuoG (Velmurugan et al., 2007).
Deleting anti-apoptotic genes should result in the creation of
the so-called “pro-apoptotic” attenuated mycobacterial vaccine
vectors that should be more immunogenic than BCG.
Mtb and to some extent BCG has the ability to actively suppress
immune responses including the induction of Th1 cytokines.
Therefore, creating mutants of BCG and other mycobacterial
vaccine vectors that lack this activity could be excellent TB vac-
cine candidates. Several of these mutants have been described.
The William Jacobs, Jr. laboratory (Albert Einstein College of
Medicine) has recently identified gain-of-function mutants that
can induce IL-2 and IL-12 cytokines that promote Th1 and pro-
tect mice from Mtb challenge (Derrick et al., 2012). A deletion
mutant of Mtb in the 85A gene (fbpA) resulted in attenua-
tion of the pathogen and appears to be highly immunogenic
(Saikolappan et al., 2012). Unlike wild type H37Rv and to a
certain extent BCG, fbpA is not suppressive for macrophages
or DC and enhances antigen presentation and the priming of
Th1 cells more effectively than BCG in mice leading to a bet-
ter protection. Mutants of the phoP response regulator in Mtb
were found to be more immunogenic than wild-typeMtb. When
used as a vaccine, the mutant was found to protect better than
BCG and the protection was associated with increased frequency
and persistence of antigen-specific central memory CD4 T cells
(Nambiar et al., 2012).
Deletion of microbial antioxidants could lead to the devel-
opment of more immunogenic BCG vaccine vectors. Indeed,
elimination of duplicated alleles encoding the oxidative stress
sigma factor H (SigH) in BCG and reducing the activity and
secretion of iron co-factored superoxide dismutase resulted in
better cellular responses to BCG. Compared to mycobacteria-
specific immune responses in mice after vaccination with BCG,
the modified vaccine (BCGsecA2sigH) induced greater IL-
12p40, RANTES, and IL-21 expression in the spleens of mice
post-immunization, more cytokine-producing CD8+ lympho-
cytes at the peak of the primary immune response, and more
IL-2-producing CD4+ lymphocytes during the memory phase.
Moreover, BCGsecA2sigH induced stronger secondary CD4+
lymphocyte responses and greater clearance of challenge bacilli
than the conventional BCG (Sadagopal et al., 2009).
Another rBCG strategy was to delete from the mycobacte-
rial genome the gene involved in phagosome maturation, zmp1
gene, (Johansen et al., 2011). The rBCGzmp1 was found to be
more immunogenic than wild-type BCG in the murine model,
suggesting that promoting phagosome maturation and lysosomal
delivery of BCG enhances immunogenicity.
An alternative strategy to create more immunogenic mycobac-
terial vector is to generate gain-of-function mycobacterial
mutants capable of inducing autophagy (Lee, 2012b). Autophagy,
an important host defense pathway, has an essential role in
both innate and adaptive immunity. However, many microbes
including Mtb have evolved mechanisms to suppress autophagic
pathways in macrophages that cause phagosomes to mature into
phagolysosomes that is detrimental to the pathogen. Generation
of “pro-autophagic” mutants of mycobacteria may have sig-
nificant application in the development of effective, safe and
persistent TB vaccines.
In addition to genetically modified BCG mutants, other
mycobacterial species are being considered as vaccine vectors
against TB and other diseases such as HIV because certain species
were found to be more immunogenic than BCG and may have a
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better safety profile. The commensal non-pathogenicM. smegma-
tis is being developed as a vaccine delivery system because it is fast
and easy to grow in culture, genetically tractable, can express large
amounts of foreign antigen and capable of inducing robust T cell
and antibody responses either as a standalone or in heterologous-
prime boost strategies (Cayabyab et al., 2006; Yu et al., 2006;
Hovav et al., 2007; Sweeney et al., 2011). M. smegmatis with an
intact esx-3 locus is lethal to mice, while a deletion mutantesx-3
(IKE strain) was controlled and cleared by MyD88-dependent
immune response (Sweeney et al., 2011). Introduction of Mtb
esx-3 genes back in M. smegmatis (IKEPLUS) resulted in pro-
tection against challenge with virulent Mtb, better than BCG.
Attempts at testing IKEPLUS in early human trials are underway.
TBVac85, an experimental live, attenuated intranasal TB
vaccine is cold-adapted, temperature-restricted engineered
Mycobacterium shottsii (Quinn, 2012). This mutant expresses
Ag85B and contains a highly immunogenic cell wall and antigenic
similarity toMtb. TBVac85 is likely to be safe in immunocompro-
mised hosts due to temperature-restricted growth attenuation.
Preliminary studies in laboratory animals showed that TBVac85
is safe and immunogenic.
Other bacterial vaccine vectors
The importance of long-term and mucosal antigen delivery was
assessed by the use of Mtb antigens delivered by live recombi-
nant Salmonella vaccine consisting of plasmids expressing fusion
proteins of type 3 secretion systems from Salmonella and Mtb
antigens ESAT-6 and CFP-10 (Juarez-Rodriguez et al., 2012). In
this model, mice receiving an oral vaccine exhibited delayed lysis
and a regulated delayed antigen synthesis, resulting in protection
against TB similar to protection induced by BCG.
Another novel delivery vector is Bacillus subtilis spores. B. sub-
tilis spores can withstand extreme conditions of low pH, desic-
cation, UV irradiation and high temperatures and are harmless
to humans, making them an ideal needle-free delivery system
of immunogens (Amuguni and Tzipori, 2012). B. subtilis spore
expressing Ag85B and ESAT-6 is currently under development as
a TB vaccine in preclinical stages (Dhandayuthapani, 2012).
HETEROLOGOUS PRIME-BOOST STRATEGIES
Recombinant BCG and other mycobacteria (i.e., M. smegmatis)
or more-immunogenic BCG mutants are being combined with
other vaccine vector prototypes in a heterologous prime-boost
strategy to induce more robust immune responses than homol-
ogous prime-boost vaccinations. Other vaccine vectors are also
being used to boostMtb-specific immune responses, elicited from
previous routine BCG vaccinations. In addition to the aforemen-
tioned viral vectors, Thomas Evans and Aeras researchers are
developing recombinant adenoviruses serotypes 4, 26, and the
chimeric rAd5HVR8 as well as recombinant human CMV vec-
tors for the delivery of TB antigens since these were found to
be potent inducers of cellular immunity, including CD8+ T cell
responses (Roberts et al., 2006; Alexander et al., 2012; Barouch
et al., 2012). We propose a heterologous prime/boost strategy
using of the DNA VRC8400 vaccine vector and the adjuvant trig-
gering Toll-like receptor 4 agonist, GLA-SE, in a heterologous
DNA prime, protein boost strategy. We found that priming mice
with VRC8400 expressing the previously identified candidate vac-
cine antigen, rMT1721 followed by boosting with the rMT1721
subunit antigen mixed with GLA induced robust CD4+ Th1 and
CD8+ T cell and antibody responses (Cayabyab et al., 2012). This
protocol is currently being tested in protection experiments.
ROUTE OF IMMUNIZATION
The dose and route of immunization of the candidate TB vac-
cine will be critical to the elicitation of protective lung immune
responses against TB. Although, pre-clinical studies in vaccine
development to TB have used and evaluated a variety of routes
of antigen delivery (intradermal, subcutaneous, intramuscular,
intra nasally, and orally) the vaccine candidates in current clin-
ical trials have been restricted to using the parenteral routes only.
Parenteral immunization has been historical successful for a vari-
ety of human vaccines to several different diseases. However,
because Mtb is a mucosal pathogen it is imperative that a vac-
cine delivery system induces protective mucosal immunity in the
lungs whereMtb initiates its infection in the alveolar macrophage.
It is possible that the lack of trials using a mucosal vaccine
delivery system for TB may be due to our limited knowledge
on how to efficiently formulate the vaccine and deliver it to a
mucosal site. In addition, it is highly debated how the route
of a mucosal vaccine antigen delivery influences the homing
specificity and anatomical distribution of resultant T lympho-
cyte responses. Since mucosal immunity and the trafficking of
T cells generated not only depends on the dose and route but
also heavily on the type of vaccine delivery system (Kaufman
and Barouch, 2009), it is difficult to predict the quality and traf-
ficking of mucosal B and T cells induced by a particular TB
vaccine candidate. There is evidence to suggest that vaccine-
elicited mucosal T cells may initially remain localized at the
site of inoculation but may subsequently become broadly dis-
tributed to other mucosal compartments and/or systemically
(Offit et al., 1991; Masopust et al., 2001, 2004). In humans,
mucosal immunization with cholera toxin B subunit, which has
been used as a mucosal adjuvant, clearly shows that the strongest
response occurs at the mucosal site where the antigen/adjuvant
formulation was delivered. However, potent responses are also
detected in the contiguous or interconnected mucosal sites (e.g.,
nasal-pulmonary tract and gut-mammary gland link in lactating
women respectively). Interestingly, nasal immunization also stim-
ulates strong immune response at unrelated anatomical sites like
the genital-vaginal mucosa (Holmgren and Czerkinsky, 2005).
Therefore, much effort needs to be placed on the pre-clinical eval-
uation of mucosal immunization in vaccine development to TB,
particularly using formulation that exploit the nasal route.
ANIMAL MODELS TO TEST TB VACCINES
Several animal models have been developed for studies of TB
disease and protection induced by candidate vaccines (Table 2).
These include Mtb infection of mice, rats, guinea pigs, rab-
bits, and monkeys. The mouse TB model is preferred because
of availability of immunological reagents, inbred and genetically
engineered strains and low cost (Orme, 2005; Ordway and Orme,
2011). However, mice fail to display the large spectrum of pul-
monary pathology seen in human infections and they do not form
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Table 2 | Animal models used in vaccine development to TB.
Disease manifestation Animal model
Mice Guinea
pigs
Rabbit Non-human
primates
Primary TB + + − +
TB meningitis − − + −
Latent TB
Cornell model + + − −
Mtb strain 18B model + + − −
Pulmonary TB
(Adult or chronic TB)
− − + +
necrotic granulomas. Infection of guinea pigs with Mtb, on the
other hand, closely resembles that of human infection by forma-
tion of caseating granulomas (Turner et al., 2003; Orme, 2005).
Because of differences in disease susceptibility, mice are gener-
ally utilized to study anti-TB immune responses, while guinea
pigs are used as a model to study progressive pathology of TB.
Infected rabbits develop lung cavitary TB that resembles many
aspects of human disease, including similarities in lung pathol-
ogy and development of caseation (Dannenberg, 2001; Subbian
et al., 2011). In addition, inoculation of rabbits with Mtb or
BCG into the subarachnoid cistern leads to the development of
a disease that clinically and histologically resembles human TB
meningitis (Behar et al., 1963; Tsenova et al., 1998, 2005). The
non-human primate model exhibits a large range of granulomas,
from caseous, to cavitary, closely resembling the human infection
(Dutta et al., 2010). Curiously and non-understandably, BCG vac-
cination protects cynomolgus monkeys (M. fascicularis) but not
rhesus monkeys (M. mulatta) against pulmonary Mtb challenge
(Langermans et al., 2001). However, the TB-susceptible monkey
model allows for the screening of vaccine candidates that could
potentially be better than BCG (Agger and Andersen, 2002).
An enormous challenge to studying latent TB infection and
evaluating vaccine candidates against this form of infection is
the unavailability of an adequate animal model that can mimic
the human LTBI infection. The latency model generally referred
to as the Cornell model was first described in the late 1950s
(McCune et al., 1956, 1966a,b; McCune and Tompsett, 1956). In
this model mice are inoculated intravenously (i.v.) with ∼2 × 106
viable bacilli of virulentMtb and the resultant infection is treated
for 12 weeks with the anti-mycobacterial drugs isoniazid (INH)
and pyrazinamide (PZA) beginning within 20min after infec-
tion. After the 12-week antibiotic treatment, no tubercle bacilli
can be cultured from the animals’ organs for many months.
However, at this time point, administration of cortisone (at
immunosuppressive doses) at 2–3 months after the interrup-
tion of the antibiotic therapy reverts this condition, and Mtb
can be cultured from lungs and spleens of ∼50% of the ani-
mals. Despite having the advantage of achieving and maintaining
for many weeks very low numbers of the tubercle bacilli within
the tissues of infected mice, this model has three major lim-
itations: (1) Dormancy is difficult to standardize because the
optimal antibiotic concentration and duration of treatment to
achieve low numbers of bacilli varies from experiment to exper-
iment; (2) Only 50% of the animals successfully treated with
antibiotic develop dormant infection, which imposes a major
complication in the interpretation of the experiments (Lenaerts
et al., 2004); and (3) Most variants of the Cornell model use
high doses of immunosuppressive agents to achieve reactiva-
tion, which by definition constitutes a complication for studies
designed to evaluate the host immune response during reactiva-
tion of the disease. An interesting alternative of animal model of
latent TB in both mice and guinea pigs has been recently pro-
posed (Kashino et al., 2006, 2008a). A streptomycin-dependent
(auxotroph) Mtb strain 18b that was isolated in 1955 in Japan
from a patient with streptomycin-resistant TB (Hashimoto, 1955)
was utilized in these studies. The Mtb 18b strain, which was
demonstrated to be entirely streptomycin-dependent, was unable
to grow unless streptomycin is present in the growth media
(Hashimoto, 1955; Honore et al., 1995). In this model of TB
latency, the Mtb 18b strain was shown to replicate in the lungs
and spleens of mice and guinea pig treated with streptomycin
and upon antibiotic treatment withdrawal the bacteria stopped
replicating concomitant with the over-expression of α-crystallin
(Kashino et al., 2006, 2008a) which is a protein member of
dormancy regulon (DosRS) and one of the most abundantly
produced protein during exposure to hypoxia and nutrient star-
vation (Cunningham and Spreadbury, 1998; Sherman et al.,
2001), leading to the conclusion that Mtb 18b mouse infection
model mimics latent TB. The Mtb 18b infection was charac-
terized by formation of granuloma and the persistence of low
numbers of viable non-replicating bacilli in mice and guinea pigs
for at least 6 months. It was also shown to induce resistance
to reinfection with virulent Mtb and potent T-cell responses to
native and purified recombinant Mtb proteins (Kashino et al.,
2006). Intriguingly, after starvation for longer periods of time,
the bacilli resume replication once streptomycin is added back
to the culture, confirming that streptomycin is required for exit-
ing the dormant state in this particular strain and was used
recently for screening of drugs against non-replicating bacteria
(Sala et al., 2010).
Finally, the recent development of humanizedmice will greatly
help to explore HIV/Mtb co-infection due to the human host
tropism of HIV. A commonly used humanized mouse model is
the NOD-SCID/3c null mice engrafted with human fetal liver and
thymic tissue, and injected intravenously with CD34+ fetal liver
cells from the same tissue source (Shultz et al., 2007; Hu and Yang,
2012). This animal model offers a unique opportunity to study
the pathogenesis of Mtb and HIV/Mtb coinfection, as well as to
determine how HIV alters protective CMI to Mtb in the context
of BCG vaccination. These studies would greatly enhance progress
toward understanding the mechanisms whereby HIV suppresses
CMI to Mtb and accelerate design and screening of TB vaccines
for HIV+ populations.
CONCLUDING REMARKS
Over the past two decades of intensive research, a myriad
of TB vaccine candidates and adjuvants have been tested.
Unfortunately, thus far, no efficacious vaccine has yet emerged.
To our view, the greatest challenge in TB vaccine development
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is the understanding of the mechanisms by which Mtb evades
and escapes the host innate and adaptive immune responses.
Therefore, it is critical to continue basic research investigations
aimed to fully elucidate immune evasion strategies used by Mtb.
Knowledge gained from these studies will undoubtedly aid in
the design of more rational vaccine approaches that will induce
the immune system to overcome the anti-host defenses launched
by Mtb, including drug resistant strains. We envision that the
successful vaccine(s) will include, perhaps novel antigens, and
importantly, vaccine delivery systems coupled to unconventional
routes of immunization (e.g., nasal) that stimulate a yet to be
unraveled type of immune response that is protective against a
pathogen that has co-evolved with its hosts for thousands of years.
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